Copyright Reports & Markets. All rights reserved.

Global Hemoglobinopathies Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Hemoglobinopathies Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Thalassemia
      • 1.4.3 Sickle Cell Disease
      • 1.4.4 Other Hb Variants Diseases
    • 1.5 Market by Application
      • 1.5.1 Global Hemoglobinopathies Market Share by Application (2019-2025)
      • 1.5.2 Blood Testing
      • 1.5.3 Genetic Testing
      • 1.5.4 Pre-Implantation Genetic Diagnosis (PGD)
      • 1.5.5 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Hemoglobinopathies Market Size
    • 2.2 Hemoglobinopathies Growth Trends by Regions
      • 2.2.1 Hemoglobinopathies Market Size by Regions (2019-2025)
      • 2.2.2 Hemoglobinopathies Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Hemoglobinopathies Market Size by by Players
      • 3.1.1 Global Hemoglobinopathies Revenue by by Players (2014-2019)
      • 3.1.2 Global Hemoglobinopathies Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Hemoglobinopathies Market Concentration Ratio (CR5 and HHI)
    • 3.2 Hemoglobinopathies Key Players Head office and Area Served
    • 3.3 Key Players Hemoglobinopathies Product/Solution/Service
    • 3.4 Date of Enter into Hemoglobinopathies Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Hemoglobinopathies Market Size by Type (2014-2019)
    • 4.2 Global Hemoglobinopathies Market Size by Application (2014-2019)

    5 North America

    • 5.1 North America Hemoglobinopathies Market Size (2014-2019)
    • 5.2 Hemoglobinopathies Key Players in North America
    • 5.3 North America Hemoglobinopathies Market Size by Type
    • 5.4 North America Hemoglobinopathies Market Size by Application

    6 Europe

    • 6.1 Europe Hemoglobinopathies Market Size (2014-2019)
    • 6.2 Hemoglobinopathies Key Players in Europe
    • 6.3 Europe Hemoglobinopathies Market Size by Type
    • 6.4 Europe Hemoglobinopathies Market Size by Application

    7 China

    • 7.1 China Hemoglobinopathies Market Size (2014-2019)
    • 7.2 Hemoglobinopathies Key Players in China
    • 7.3 China Hemoglobinopathies Market Size by Type
    • 7.4 China Hemoglobinopathies Market Size by Application

    8 Japan

    • 8.1 Japan Hemoglobinopathies Market Size (2014-2019)
    • 8.2 Hemoglobinopathies Key Players in Japan
    • 8.3 Japan Hemoglobinopathies Market Size by Type
    • 8.4 Japan Hemoglobinopathies Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Hemoglobinopathies Market Size (2014-2019)
    • 9.2 Hemoglobinopathies Key Players in Southeast Asia
    • 9.3 Southeast Asia Hemoglobinopathies Market Size by Type
    • 9.4 Southeast Asia Hemoglobinopathies Market Size by Application

    10 India

    • 10.1 India Hemoglobinopathies Market Size (2014-2019)
    • 10.2 Hemoglobinopathies Key Players in India
    • 10.3 India Hemoglobinopathies Market Size by Type
    • 10.4 India Hemoglobinopathies Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Hemoglobinopathies Market Size (2014-2019)
    • 11.2 Hemoglobinopathies Key Players in Central & South America
    • 11.3 Central & South America Hemoglobinopathies Market Size by Type
    • 11.4 Central & South America Hemoglobinopathies Market Size by Application

    12 International Players Profiles

    • 12.1 Gamida Cell
      • 12.1.1 Gamida Cell Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Hemoglobinopathies Introduction
      • 12.1.4 Gamida Cell Revenue in Hemoglobinopathies Business (2014-2019))
      • 12.1.5 Gamida Cell Recent Development
    • 12.2 Alnylam Pharmaceuticals
      • 12.2.1 Alnylam Pharmaceuticals Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Hemoglobinopathies Introduction
      • 12.2.4 Alnylam Pharmaceuticals Revenue in Hemoglobinopathies Business (2014-2019)
      • 12.2.5 Alnylam Pharmaceuticals Recent Development
    • 12.3 Sanofi
      • 12.3.1 Sanofi Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Hemoglobinopathies Introduction
      • 12.3.4 Sanofi Revenue in Hemoglobinopathies Business (2014-2019)
      • 12.3.5 Sanofi Recent Development
    • 12.4 Sangamo Therapeutics Inc.
      • 12.4.1 Sangamo Therapeutics Inc. Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Hemoglobinopathies Introduction
      • 12.4.4 Sangamo Therapeutics Inc. Revenue in Hemoglobinopathies Business (2014-2019)
      • 12.4.5 Sangamo Therapeutics Inc. Recent Development
    • 12.5 Global Blood Therapeutics
      • 12.5.1 Global Blood Therapeutics Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Hemoglobinopathies Introduction
      • 12.5.4 Global Blood Therapeutics Revenue in Hemoglobinopathies Business (2014-2019)
      • 12.5.5 Global Blood Therapeutics Recent Development
    • 12.6 Bluebird Bio
      • 12.6.1 Bluebird Bio Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Hemoglobinopathies Introduction
      • 12.6.4 Bluebird Bio Revenue in Hemoglobinopathies Business (2014-2019)
      • 12.6.5 Bluebird Bio Recent Development
    • 12.7 Emmaus Life Sciences Inc.
      • 12.7.1 Emmaus Life Sciences Inc. Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Hemoglobinopathies Introduction
      • 12.7.4 Emmaus Life Sciences Inc. Revenue in Hemoglobinopathies Business (2014-2019)
      • 12.7.5 Emmaus Life Sciences Inc. Recent Development
    • 12.8 Prolong Pharmaceuticals
      • 12.8.1 Prolong Pharmaceuticals Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Hemoglobinopathies Introduction
      • 12.8.4 Prolong Pharmaceuticals Revenue in Hemoglobinopathies Business (2014-2019)
      • 12.8.5 Prolong Pharmaceuticals Recent Development
    • 12.9 Celgene Corporation
      • 12.9.1 Celgene Corporation Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Hemoglobinopathies Introduction
      • 12.9.4 Celgene Corporation Revenue in Hemoglobinopathies Business (2014-2019)
      • 12.9.5 Celgene Corporation Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Product (2019-2025)
    • 13.2 Market Size Forecast by Application (2019-2025)
    • 13.3 Market Size Forecast by Regions
    • 13.4 North America
    • 13.5 Europe
    • 13.6 China
    • 13.7 Japan
    • 13.8 Southeast Asia
    • 13.9 India
    • 13.10 Central & South America

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 15.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Hemoglobinopathy or Hemoglobinopathies is the medical term for a group of blood disorders and diseases that affect red blood cells. It can be a kind of genetic defect that results in abnormal structure of one of the globin chains of the hemoglobin molecule.
      Increasing cases of hemoglobinopathies, especially in regions such as Southeast Asia and Africa, is one of the major growth drivers.
      In 2018, the global Hemoglobinopathies market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Hemoglobinopathies status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Hemoglobinopathies development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

      The key players covered in this study
      Gamida Cell
      Alnylam Pharmaceuticals
      Sanofi
      Sangamo Therapeutics Inc.
      Global Blood Therapeutics
      Bluebird Bio
      Emmaus Life Sciences Inc.
      Prolong Pharmaceuticals
      Celgene Corporation

      Market segment by Type, the product can be split into
      By Type
      By Therapy

      Market segment by Application, split into
      Blood Testing
      Genetic Testing
      Pre-Implantation Genetic Diagnosis (PGD)
      Others

      Market segment by Regions/Countries, this report covers
      North America
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Hemoglobinopathies status, future forecast, growth opportunity, key market and key players.
      To present the Hemoglobinopathies development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Hemoglobinopathies are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
      Buy now